Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Up to $13.21

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) gapped up prior to trading on Tuesday . The stock had previously closed at $13.21, but opened at $13.77. Neumora Therapeutics shares last traded at $13.36, with a volume of 26,625 shares.

Analyst Upgrades and Downgrades

NMRA has been the subject of a number of research analyst reports. Royal Bank of Canada reissued an “outperform” rating and set a $29.00 target price on shares of Neumora Therapeutics in a report on Wednesday, September 4th. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price objective on shares of Neumora Therapeutics in a research note on Thursday, September 12th. HC Wainwright started coverage on Neumora Therapeutics in a report on Tuesday. They issued a “buy” rating and a $30.00 price objective on the stock. Finally, Mizuho assumed coverage on shares of Neumora Therapeutics in a report on Monday, July 8th. They set an “outperform” rating and a $20.00 target price for the company. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Neumora Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $22.90.

Neumora Therapeutics Stock Performance

The stock has a 50 day simple moving average of $11.90 and a two-hundred day simple moving average of $11.18.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.37) EPS for the quarter, hitting the consensus estimate of ($0.37). Equities analysts forecast that Neumora Therapeutics, Inc. will post -1.51 EPS for the current fiscal year.

Insider Buying and Selling at Neumora Therapeutics

In other news, insider Robert A. Lenz sold 30,788 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $11.81, for a total transaction of $363,606.28. Following the completion of the sale, the insider now owns 339,205 shares in the company, valued at approximately $4,006,011.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Joshua Pinto sold 31,642 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $11.78, for a total value of $372,742.76. Following the sale, the chief financial officer now directly owns 154,658 shares in the company, valued at approximately $1,821,871.24. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Robert A. Lenz sold 30,788 shares of the stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $11.81, for a total transaction of $363,606.28. Following the transaction, the insider now directly owns 339,205 shares of the company’s stock, valued at approximately $4,006,011.05. The disclosure for this sale can be found here. Insiders have sold 90,926 shares of company stock worth $1,067,758 in the last ninety days. 26.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Neumora Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Amalgamated Bank increased its holdings in Neumora Therapeutics by 472.8% in the 2nd quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock valued at $29,000 after purchasing an additional 2,402 shares during the last quarter. Quarry LP purchased a new position in shares of Neumora Therapeutics during the second quarter worth $98,000. SkyOak Wealth LLC acquired a new stake in shares of Neumora Therapeutics in the second quarter valued at $147,000. Principal Financial Group Inc. acquired a new stake in shares of Neumora Therapeutics in the second quarter valued at $166,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Neumora Therapeutics in the 2nd quarter valued at $566,000. 47.65% of the stock is owned by hedge funds and other institutional investors.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.